Listed

Ovid Therapeutics Inc.

OVIDNasdaqCIK 1636651HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$733.0kRevenue, Q2 FY2026, three months to 2026-06-30$733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 13, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$733.0kRevenue, Q2 FY2026, three months to 2026-06-30$733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure−88.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−2141.6%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$15.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure−2060.7 pts on a year earlier
  • Net margin−2047.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure−1972.9 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$733.0kOperating margin −2141.6%
Diluted EPS−$0.20, Q3 FY2024
Free cash flow−$10.4m, Q4 FY2025
Ovid Therapeutics Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.2Revenue, Q3 FY2024, three months to 2024-09-30$173.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Report this figure0.1Revenue, Q4 FY2024, three months to 2024-12-31$76.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2025, three months to 2025-03-31$130.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033864.Report this figure6.3Revenue, Q2 FY2025, three months to 2025-06-30$6.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure0.1Revenue, Q3 FY2025, three months to 2025-09-30$132.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Report this figure0.7Revenue, Q4 FY2025, three months to 2025-12-31$718.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033864.Report this figure0.7Revenue, Q2 FY2026, three months to 2026-06-30$733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(7645.1%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$13.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Revenue: $173.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Report this figure(14107.9%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Revenue: $76.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figure(9653.8%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$12.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-033864.Revenue: $130.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033864.Report this figure(80.9%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $6.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure(9487.1%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$12.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Revenue: $132.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Report this figure(1712.1%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Revenue: $718.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)(2141.6%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$15.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure
Net margin%(8096.0%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Revenue: $173.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Report this figure(12175.0%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$9.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Revenue: $76.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figure(7873.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$10.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $130.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033864.Report this figure(74.7%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$4.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $6.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure(9210.6%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$12.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Revenue: $132.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001636651-25-000012.Report this figure1345.8%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Revenue: $718.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)(2047.6%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Revenue: $733.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001628280-26-056498.Report this figure
Diluted EPS$ per share(0.20)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001628280-24-046868.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(15.0)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$15.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001636651-25-000012. Derived: 9-month figure less the 6-month figure.Capital expenditure: −$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001636651-25-000012. Derived: 9-month figure less the 6-month figure.Report this figure(10.0)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Capital expenditure: $22.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figure(10.3)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001628280-26-033864.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001628280-25-024913.Report this figure(4.8)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001628280-26-056498. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001628280-25-040008. Derived: 6-month figure less the 3-month figure.Report this figure(12.9)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$12.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001636651-25-000012. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001636651-25-000012. Derived: 9-month figure less the 6-month figure.Report this figure(10.4)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001628280-26-019438. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$7.3mOperating margin −585.2%
Diluted EPS−$0.74, FY2023
Free cash flow−$38.3m, FY2025
Ovid Therapeutics Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m208Revenue, FY2021, twelve months to 2021-12-31$208.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-13, accession 0001628280-23-007648.Report this figure1.5Revenue, FY2022, twelve months to 2022-12-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-08, accession 0001628280-24-009809.Report this figure0.4Revenue, FY2023, twelve months to 2023-12-31$392.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0001628280-25-011844.Report this figure0.6Revenue, FY2024, twelve months to 2024-12-31$566.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure7.3Revenue, FY2025, twelve months to 2025-12-31$7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%59.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $124.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-13, accession 0001628280-23-007648.Revenue: $208.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-13, accession 0001628280-23-007648.Report this figure(3696.4%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$55.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-08, accession 0001628280-24-009809.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-08, accession 0001628280-24-009809.Report this figure(15122.7%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$59.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-11, accession 0001628280-25-011844.Revenue: $392.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0001628280-25-011844.Report this figure(10933.7%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$61.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438.Revenue: $566.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure(585.2%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$42.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure
Net margin%58.9%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $122.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-13, accession 0001628280-23-007648.Revenue: $208.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-13, accession 0001628280-23-007648.Report this figure(3604.7%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$54.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-08, accession 0001628280-24-009809.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-08, accession 0001628280-24-009809.Report this figure(13351.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$52.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-11, accession 0001628280-25-011844.Revenue: $392.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0001628280-25-011844.Report this figure(4670.1%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$26.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438.Revenue: $566.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure(240.1%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$17.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001628280-26-019438.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure
Diluted EPS$ per share1.76Diluted EPS, FY2021, twelve months to 2021-12-31$1.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-13, accession 0001628280-23-007648.Report this figure(0.77)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-08, accession 0001628280-24-009809.Report this figure(0.74)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-08, accession 0001628280-24-009809.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m118Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $118.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-13, accession 0001628280-23-007648.Capital expenditure: $184.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-13, accession 0001628280-23-007648.Report this figure(56.5)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$55.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-08, accession 0001628280-24-009809.Capital expenditure: $1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-08, accession 0001628280-24-009809.Report this figure(45.8)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$45.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-11, accession 0001628280-25-011844.Capital expenditure: $40.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-11, accession 0001628280-25-011844.Report this figure(56.0)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$56.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001628280-26-019438.Capital expenditure: $71.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure(38.3)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$38.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001628280-26-019438.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001628280-26-019438.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Ovid Therapeutics Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Jupiter Topco LLC2026-06-30$55.9m20,741,234Not compared
EVENTIDE ASSET MANAGEMENT, LLC2026-06-30$31.8m11,812,241Added+1,895,330
BlackRock, Inc.2026-06-30$29.1m10,823,480Added+9,290,197
RA CAPITAL MANAGEMENT, L.P.2026-06-30$28.2m10,500,968Reduced−213,032
Affinity Asset Advisors, LLC2026-06-30$27.3m10,144,562Reduced−491,756
JANUS HENDERSON GROUP PLC2026-03-31$23.7m10,714,000Not compared
STATE STREET CORP2026-06-30$21.3m7,900,765Added+7,380,482
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$20.9m7,760,114Added+2,501,868
ADAR1 Capital Management, LLC2026-06-30$20.0m7,417,479Added+2,873,366
Balyasny Asset Management L.P.2026-06-30$18.1m6,719,076Added+1,186,003

Recent filings

All 519 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Ovid Therapeutics Inc., recent filings
FiledFormWhat it isAccession number
2026-08-1308:33 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-056498
2026-08-1308:32 ET8-K9.01 Financial statements and exhibits0001628280-26-056497
2026-07-0807:03 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-047584
2026-06-1109:03 ET8-K5.07 Shareholder vote results0001628280-26-042396
2026-06-0307:03 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-040038
2026-05-1207:06 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-033864
2026-05-1207:04 ET8-K9.01 Financial statements and exhibits0001628280-26-033859
2026-04-2717:11 ETDEF 14AProxy statementPeriod 2025-12-310001628280-26-027621
2026-04-2008:16 ET8-K8.01 Other events0001628280-26-025926
2026-03-1816:25 ET10-KAnnual reportPeriod 2025-12-310001628280-26-019438

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 18, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1636651
Tickers
OVID
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.